Objective To compare number and level of positive lymph nodes (PLNs) to see which is a better predictor of prognosis for node-pesitive colon cancer. Methods Seventy-eight patients had undergone curative resection for node-positive colon cancer. Calculated the cumulative 3-year, 5-year survival rates and explored the relation to survival rates between number (pN1/pN2) and level (level Ⅰ/Ⅱ)of PLNs. Results The 3-year, 5-yesr survival rotes of colon cancer with PLNs was 73.1%(57/78), 65.4%(51/78). There was statistical difference of 3-year, 5-year survival rates between pN1 group and pN2 group [77.8% (42/54)vs 62.5% (15/24), 72.2% (39/54)vs 50.0% (12/24),P =0.004], but no statistical difference between level Ⅰ group and level Ⅱ group [77.5 %(31/40) vs 68.4%(26/38), 67.5%(27/40) vs 63.2% (24/38),P=0.349]. Conclusion In node-positive colon cancer, number of PLNs predicts prognosis better than level of PLNs.

ObjectiveTo investigate the diagnosis and correlative factors of suspected severe acute respiratory synd rome (SARS) cases, and finally, complete the diagnosis and treatment.MethodsTo analyze the clinical, laboratory data,chest radiog raph and treatment of 100 suspected SARS cases.ResultsAmong 100 suspected SARS cases,66 were diagnosed as SARS,4 were mycoplasma l pneumonia, 2 were pulmonary tuberculosis,the others were general bacteria pne umonia.Conclusions SARS hasn't characteristic clin ical manifestation.Because there is not a gold diagnosis standard up to now, the disinfection and isolation of suspected SARS cases should be treated as SARS c ases. In order to prevent missed and misdiagnosis, the diagnosis and treatment s hould be synthetically thought.

Objective To explore the effect Tiaoli-Qixue decoction on bleeding and coagulation during perioperative period of total hip arthroplasty (THA).Methods A total of 180 THA patients who met the inclusion criteria were randomly divided into three groups with 60 cases in each group.All patients underwent routine anti-infection treatment after unilateral THA through lateral hip approach.The patients took the Tiaoli-Qixue decoction 3 days before THA in the treatment group.The patients in the Xuesaitong control group received intravenous Xuesaitong on the day of operation and rivaroxaban tablets were administered orally on the day of operation in the westem medicine control group.The continuous medication was administered until 7 days after operation in three groups.The amount of hemorrhage and drainage after operation were recorded and the total amount of dominant hemorrhage was calculated.The Degao M4 semi-automatic hemagglutination instrument was used to detect plasma D-dimer level and observe thrombosis.Harris scale was used before and after operation to calculate the excellent and good rates of Harris score.Results The total amount of dominant hemorrhage (376.67 ± 61.44 ml vs.400.08 ± 61.16 ml,413.33 ± 53.76 ml,F=5.963),intraoperative hemorrhage (165.50 ± 15.67 ml vs.174.75 ± 14.68 ml,175.42 ± 11.13 ml,F=9.452) and postoperative drainage (211.17 ± 58.12 ml vs.225.33 ± 56.93 ml,237.92 ± 54.28 ml,F=3.370) in the treatment group of traditional Chinese medicine were significanlty less than those in the Xuesaitong control group and the Western medicine control group (P＜0.01 or P＜0.05).On the 7th day after operation,there were 6 cases of thrombosis in the treatment group of traditional Chinese medicine,4 cases in the Xuesaitong control group and 4 cases in the Western medicine control group.There was no significant difference between the three groups (x2=0.667,P=0.881).Six months after operation,the excellent and good rate of that the treatment group of traditional Chinese medicine was 45.0％ (27/60),which of the the Xuesaitong control group was 11.7％ (7/60),and which of the the Western medicine control group was 13.3％ (8/60).There was significant difference among the three groups.Conclusions The Tiaoli-Qixue decoction bleeding and coagulation can reduce the amount of dominant bleeding during perioperative period in patients with THA,and effectively prevent and treat deep venous thrombosis of lower limbs after THA.

Objective: To investigate the clinical effect and safety of entecavir capsules in the treatment of treatment-naïve HBeAg-positive patients with chronic hepatitis B (CHB). Methods: A total of 158 HBeAg-positive CHB patients were given oral entecavir capsules at a dose of 0.5 mg/time once a day for 144 weeks. Clinical outcome and safety were evaluated at baseline and at 24, 48, 72, 96, 120, and 144 weeks of treatment respectively. The Fisher’s exact test was used for the analysis of categorical data. Results: After 144 weeks of treatment, 90.91% of all patients achieved virologic response (< 69 IU/ml), the normalization rate of alanine aminotransferase was 88.18%, the clearance rate of HBeAg was 33.33%, and the seroconversion rate of HBeAg was 24.07%. Of all patients, 2 dropped out due to adverse events and 5 experienced serious adverse reactions. Conclusion Entecavir capsules can inhibit viral replication and have good safety in treatment-naïve HBeAg-positive CHB patients.